Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 curcumin studies
Outcomes in curcumin studies. Studies typically use advanced formulations for greatly improved bioavailability.
00.250.50.7511.251.51.752+Dound (RCT)33%0.67 [0.54-0.82]6 pt. scale100 (n)100 (n)CT​1Improvement, RR [CI]TreatmentControlSaber-Moghaddam94%0.06 [0.00-0.93]progression0/218/20Pawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Tau​2 = 0.72; I​2 = 56.2%Early treatment72%0.28 [0.09-0.91]2/22122/22072% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies59%0.41 [0.20-0.82]6/24130/24059% improvement5 curcumin COVID-19 studiesc19curcumin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.25; I​2 = 43.4%; Z = 2.51Effect extraction pre-specifiedFavors curcuminFavors control 00.250.50.7511.251.51.752+Pawar (DB RCT)82%0.18 [0.04-0.79]2/7011/70Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7011/7082% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies65%0.35 [0.13-0.90]6/9019/9065% improvement2 curcumin COVID-19 mortality resultsc19curcumin.com Sep 24, 2021Tau​2 = 0.09; I​2 = 18.2%; Z = 2.18Favors curcuminFavors control 00.250.50.7511.251.51.752+Saber-Moghaddam45%0.55 [0.39-0.79]hosp. time21 (n)20 (n)Improvement, RR [CI]TreatmentControlAhmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Tau​2 = 0.00; I​2 = 0.0%Early treatment46%0.54 [0.38-0.77]0/513/5046% improvementAll studies46%0.54 [0.38-0.77]0/513/5046% improvement2 curcumin COVID-19 hospitalization resultsc19curcumin.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.44Favors curcuminFavors control 00.250.50.7511.251.51.752+Dound (RCT)33%0.67 [0.54-0.82]6 pt. scale100 (n)100 (n)CT​1Improvement, RR [CI]TreatmentControlSaber-Moghaddam94%0.06 [0.00-0.93]progression0/218/20Pawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Tau​2 = 0.72; I​2 = 56.2%Early treatment72%0.28 [0.09-0.91]2/22122/22072% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies59%0.41 [0.20-0.82]6/24130/24059% improvement5 curcumin COVID-19 serious outcomesc19curcumin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.25; I​2 = 43.4%; Z = 2.51Effect extraction pre-specifiedFavors curcuminFavors control 00.250.50.7511.251.51.752+Dound (RCT)33%0.67 [0.54-0.82]6 pt. scale100 (n)100 (n)CT​1Improvement, RR [CI]TreatmentControlPawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Tau​2 = 0.45; I​2 = 49.7%Early treatment61%0.39 [0.14-1.12]2/20014/20061% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies48%0.52 [0.30-0.89]6/22022/22048% improvement4 curcumin COVID-19 Randomized Controlled Trialsc19curcumin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.11; I​2 = 28.7%; Z = 2.39Effect extraction pre-specifiedFavors curcuminFavors control 00.250.50.7511.251.51.752+Pawar (DB RCT)82%0.18 [0.04-0.79]2/7011/70Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7011/7082% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies65%0.35 [0.13-0.90]6/9019/9065% improvement2 curcumin COVID-19 RCT mortality resultsc19curcumin.com Sep 24, 2021Tau​2 = 0.09; I​2 = 18.2%; Z = 2.18Favors curcuminFavors control 00.250.50.7511.251.51.752+Dound (RCT)33%0.67 [0.54-0.82]6 pt. scale100 (n)100 (n)CT​1Improvement, RR [CI]TreatmentControlSaber-Moghaddam94%0.06 [0.00-0.93]progression0/218/20Pawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Tau​2 = 0.72; I​2 = 56.2%Early treatment72%0.28 [0.09-0.91]2/22122/22072% improvementValizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment50%0.50 [0.18-1.40]4/208/2050% improvementAll studies59%0.41 [0.20-0.82]6/24130/24059% improvement5 curcumin COVID-19 peer reviewed trialsc19curcumin.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 0.25; I​2 = 43.4%; Z = 2.51Effect extraction pre-specifiedFavors curcuminFavors control 00.250.50.7511.251.51.752+Dound (RCT)33%0.67 [0.54-0.82]6 pt. scale100 (n)100 (n)CT​1Improvement, RR [CI]TreatmentControlSaber-Moghaddam94%0.06 [0.00-0.93]progression0/218/20Saber-Moghaddam38%0.62 [0.39-0.96]no recov.11/2117/20Saber-Moghaddam45%0.55 [0.39-0.79]hosp. time21 (n)20 (n)Pawar (DB RCT)82%0.18 [0.04-0.79]death2/7011/70Pawar (DB RCT)60%0.40 [0.09-1.75]death2/155/15Pawar (DB RCT)91%0.09 [0.01-1.56]death0/255/25Pawar (DB RCT)67%0.33 [0.01-7.87]death0/301/30Ahmadi (DB RCT)86%0.14 [0.01-2.65]hosp.0/303/30Ahmadi (DB RCT)21%0.79 [0.48-1.31]recov. time30 (n)30 (n)Valizadeh (DB RCT)50%0.50 [0.18-1.40]death4/208/20curcumin COVID-19 outcomesc19curcumin.com Sep 24, 2021Favors curcuminFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit